Aclaris Therapeutics (ACRS) Shares Outstanding (2014 - 2026)

Aclaris Therapeutics' Shares Outstanding history runs 13 years deep, the most recent figure standing at $139.7 million for Q1 2026.

• In Q1 2026, Shares Outstanding rose 28.99% year-over-year to $139.7 million; the TTM figure through Mar 2026 stood at $139.7 million (up 28.99% YoY), while the FY2025 annual figure was $120.5 million, up 11.73% from the prior year.
• Shares Outstanding was $139.7 million for Q1 2026 at Aclaris Therapeutics, up from $120.5 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $139.7 million in Q1 2026 to a low of $61.7 million in Q1 2022.
• Historically, Shares Outstanding has averaged $85.2 million across 5 years, with a median of $71.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding surged 723.2% in 2022, then rose 0.8% in 2024.
• A 5-year view of Shares Outstanding shows it stood at $66.7 million in 2022, then rose by 6.31% to $70.9 million in 2023, then soared by 52.13% to $107.9 million in 2024, then gained by 11.73% to $120.5 million in 2025, then climbed by 15.9% to $139.7 million in 2026.
• The last three Shares Outstanding figures came in at $139.7 million (Q1 2026), $120.5 million (Q4 2025), and $108.3 million (Q3 2025), per Business Quant data.